EGFR and non-small cell lung carcinoma: EGFR Y891D (corresponding to Y867 in mature EGFR numbering without the 24 residues of the signal peptide) has been reported previously in EGFR-mutated NSCLC as an acquired alteration associated with clinical resistance to first generation EGFR inhibitors21,22.